Homeopathic treatment of heavy bleeding during periods

A single arm trial to evaluate the role of Indian-origin homoeopathic drugs in management of abnormal uterine bleeding in women of childbearing age

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052191

Enrollment

Registered

2023-05-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention1: Indian-origin homoeopathic medicines in centesimal potencies: Intervention is planned as administering the indicated Indian-origin homoeopathic medicines based on symptom similarity, in

dosage and repetition will be according to the individual requirement of the case. Medicines will be procured from Good Manufacturing Practice certified firm. Dietary advice will be advised to the pat

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed cases of AUB. 2. Women of reproductive age group (15 to 49 yrs). 3. Patients who are willing to give assent and/or consent for participating in the study. 4. Patients who can read/understand Bengali/Hindi/English. 5. Patients with matching symptom similarity with any one of the Indian-origin Homoeopathic drugs.

Exclusion criteria

Exclusion criteria: 1. Pregnant and puerperal women or lactating mothers. 2. Patients suffering from AUB due to Intra Uterine Devices (IUDs). 3. Patients in advanced pathology, or having doubtful hyperplasia or malignancy. 4. Patients having bleeding other than uterine origin. 5. Patients suffering from severe anemia (blood hemoglobin less than 8 gm/dl). 6. Patients with diagnosed cases of unstable psychiatric illness or other systemic diseases affecting quality of life. 7. Substance abuse and/or dependence. 8. Simultaneous participation in any other clinical trial. 9. Vulnerable population - unconscious, non-ambulatory, too sick for consultation, differently abled, terminally, or critically ill patients and mentally incompetent people.

Design outcomes

Primary

Measure	Time frame
Pictorial Blood Loss Assessment Chart (PBAC)Timepoint: At baseline, every month, upto 4 months	—

Secondary

Measure	Time frame
SF-36 Health Survey Questionnaire 1.0Timepoint: At baseline, every month, upto 4 months	—

Countries

India

Contacts

Public ContactOmpriya Mishra

National Institute of Homoeopathy

drompriyanih@gmail.com8240359414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026